Han-Zhong Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6068997/publications.pdf

Version: 2024-02-01

100 1,081 18 26
papers citations h-index g-index

125 125 125 1680
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. Oncologist, 2019, 24, e702-e708.	3.7	70
2	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Science, 2021, 112, 305-313.	3.9	62
3	Current status of diagnosis and treatment of bladder cancer in China – Analyses of Chinese Bladder Cancer Consortium database. Asian Journal of Urology, 2015, 2, 63-69.	1.2	52
4	Moving Away from Exhaustion: How Core Self-Evaluations Influence Academic Burnout. PLoS ONE, 2014, 9, e87152.	2.5	42
5	Transperineal Ultrasound-Guided Saturation Biopsies Using 11-Region Template of Prostate: Report of 303 Cases. Urology, 2007, 70, 1157-1161.	1.0	40
6	Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC. Frontiers in Oncology, 2019, 9, 663.	2.8	32
7	An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer. Aging, 2019, 11, 6930-6940.	3.1	31
8	Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma. PLoS ONE, 2015, 10, e0115896.	2.5	30
9	MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2. Oncology Reports, 2017, 38, 2727-2734.	2.6	27
10	Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study on short-term oncologic prognosis. OncoTargets and Therapy, 2018, Volume 11, 1625-1632.	2.0	26
11	Retroperitoneal Laparoscopic Management of Paraganglioma: A Single Institute Experience. PLoS ONE, 2016, 11, e0149433.	2.5	25
12	Transperineal templateâ€guided prostate biopsy: 10Âyears of experience. BJU International, 2016, 117, 424-429.	2. 5	24
13	Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet Journal of Rare Diseases, 2018, 13, 43.	2.7	24
14	Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor A. Oncology Reports, 2016, 35, 1778-1786.	2.6	23
15	A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naÃve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian Journal of Urology, 2017, 4, 75-85.	1.2	23
16	Urinary Exosomal CA9 mRNA as a Novel Liquid Biopsy for Molecular Diagnosis of Bladder Cancer. International Journal of Nanomedicine, 2021, Volume 16, 4805-4811.	6.7	21
17	miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma. Laboratory Investigation, 2018, 98, 856-870.	3.7	20
18	Relationship among diet habit and lower urinary tract symptoms and sexual function in outpatient-based males with LUTS/BPH: a multiregional and cross-sectional study in China. BMJ Open, 2016, 6, e010863.	1.9	19

#	Article	IF	Citations
19	The biological functions and mechanism of miR-212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2. Oncology Reports, 2017, 38, 1411-1419.	2.6	19
20	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology, 2020, 10, 664.	2.8	19
21	Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults. Oncology Letters, 2015, 10, 2865-2870.	1.8	17
22	The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens. BMC Cancer, 2018, 18, 1205.	2.6	17
23	Assessment of Tuberous Sclerosis Complex Associated With Renal Lesions by Targeted Next-generation Sequencing in Mainland China. Urology, 2017, 101, 170.e1-170.e7.	1.0	16
24	Comparison of lesions detected and undetected by templateâ€guided transperineal saturation prostate biopsy. BJU International, 2018, 121, 415-420.	2.5	16
25	Three-Dimensional Visualization Technology Used in Pancreatic Surgery: a Valuable Tool for Surgical Trainees. Journal of Gastrointestinal Surgery, 2020, 24, 866-873.	1.7	14
26	iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma. BioMed Research International, 2015, 2015, 1-6.	1.9	13
27	Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence-specific RNA capture. Oncology Reports, 2015, 34, 2439-2444.	2.6	13
28	An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. Asian Journal of Andrology, 2016, 18, 773.	1.6	13
29	When to Introduce Three-Dimensional Visualization Technology into Surgical Residency: A Randomized Controlled Trial. Journal of Medical Systems, 2019, 43, 71.	3.6	13
30	Efficacy and safety of tadalafil 5Âmg onceâ€daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phaseÂ3, randomized, doubleâ€blind, parallel, placebo―and tamsulosinâ€controlled study. International Journal of Urology, 2019, 26, 192-200.	1.0	13
31	A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. International Urology and Nephrology, 2020, 52, 437-446.	1.4	13
32	lgG4-related inflammatory pseudotumor of the kidney mimicking renal cell carcinoma: A case report. Oncology Letters, 2016, 11, 3438-3440.	1.8	12
33	Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1. Oncology Reports, 2017, 38, 837-842.	2.6	12
34	Experience of Retroperitoneal Laparoscopic Treatment on Pheochromocytoma. Urology, 2011, 77, 131-135.	1.0	11
35	Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer. International Journal of Surgery, 2015, 15, 113-116.	2.7	10
36	CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. International Urology and Nephrology, 2019, 51, 671-676.	1.4	10

#	Article	IF	CITATIONS
37	Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study. BMC Cancer, 2020, 20, 340.	2.6	10
38	Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease. International Journal of Clinical and Experimental Medicine, 2015, 8, 19311-7.	1.3	10
39	Role of Adrenalectomy in Ectopic ACTH Syndrome. Endocrine Journal, 2005, 52, 721-726.	1.6	9
40	Comparison of Partial and Radical Laparascopic Nephrectomy: Long-Term Outcomes for Clinical T1b Renal Cell Carcinoma. Urology Journal, 2018, 15, 16-20.	0.4	9
41	Single-cell transcriptome analysis identifies a unique tumor cell type producing multiple hormones in ectopic ACTH and CRH secreting pheochromocytoma. ELife, 2021, 10, .	6.0	9
42	Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer. International Urology and Nephrology, 2016, 48, 481-487.	1.4	8
43	Clinicopathologic Comparison of Urothelial Bladder Carcinoma in Young and Elder Patients. Pathology and Oncology Research, 2016, 22, 67-70.	1.9	8
44	Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. Asian Journal of Urology, 2019, 6, 114-121.	1.2	8
45	Effect of a risk-stratified intervention strategy on surgical complications: experience from a multicentre prospective study in China. BMJ Open, 2019, 9, e025401.	1.9	8
46	Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker. Frontiers in Oncology, 2020, 10, 1507.	2.8	7
47	Development of a nomogram combining multiparametric magnetic resonance imaging and PSAâ€related parameters to enhance the detection of clinically significant cancer across different region. Prostate, 2022, 82, 556-565.	2.3	7
48	Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro. Cancer Cell International, 2015, 15, 26.	4.1	6
49	Diagnosis and Treatment of Adrenocortical Oncocytoma: Case Report of Five Cases and Review of the Literature. Frontiers in Oncology, 2019, 9, 338.	2.8	6
50	Is Prophylactic Steroid Treatment Mandatory for Subclinical Cushing Syndrome After Unilateral Laparoscopic Adrenalectomy?. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, 31-35.	0.8	6
51	Radiumâ€223 in Asian patients with castrationâ€resistant prostate cancer with symptomatic bone metastases: A singleâ€arm phase 3 study. Asia-Pacific Journal of Clinical Oncology, 2020, 17, 462-470.	1.1	6
52	Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer. Lancet Oncology, The, 2017, 18, e187.	10.7	5
53	125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. Oncology Letters, 2019, 18, 72-80.	1.8	5
54	A multicenter observational study of the realâ€world use of docetaxel for metastatic castrationâ€resistant prostate cancer in China. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 144-150.	1.1	5

#	Article	lF	CITATIONS
55	Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China. Orphanet Journal of Rare Diseases, 2021, 16, 299.	2.7	5
56	Unilateral lesion detected on preoperative multiparametric magnetic resonance imaging and MRI/US fusion-guided prostate biopsy is not an appropriate indication for focal therapy in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 730.e17-730.e22.	1.6	5
57	RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2015, 33, 4518-4518.	1.6	5
58	Transumbilical laparoendoscopic singleâ€site surgery versus conventional laparoscopy for the resection of retroperitoneal paragangliomas. International Journal of Urology, 2015, 22, 844-849.	1.0	4
59	The characteristics and spatial distributions of prostate cancer in autopsy specimens. Prostate, 2021, 81, 135-141.	2.3	4
60	Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/CBP/FOXM1 signaling pathway. International Journal of Oncology, 2020, 57, 314-324.	3.3	4
61	A 30-Year, Single-Center Experience of Unilateral Adrenalectomy for Primary Bilateral Macronodular Adrenal Hyperplasia. Endocrine Practice, 2022, 28, 690-695.	2.1	4
62	Magnetic resonance imaging is useful for diagnosis and evaluation of recurrent intravenous leiomyomatosis before surgery. Fertility and Sterility, 2009, 92, 1150-1152.	1.0	3
63	Preliminary Application of WCX Magnetic Bead-Based Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry in Analyzing the Urine of Renal Clear Cell Carcinoma. Chinese Medical Sciences Journal, 2017, 32, 248.	0.4	3
64	Intraoperative Vaginal Perforation During Various Mid-Urethral Sling Procedures Treating Female Stress Urinary Incontinence. Journal of Investigative Surgery, 2020, 33, 203-210.	1.3	3
65	Clinical significance of phenotyping and karyotyping of detecting circulating tumor cells in renal cell carcinoma using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH). International Urology and Nephrology, 2020, 52, 2281-2287.	1.4	3
66	Comparison of standard absorbable sutures with self-retaining sutures in retroperitoneoscopic partial nephrectomy: a retrospective study of 68 patients. Urology Journal, 2014, 11, 1878-83.	0.4	3
67	Expression of \hat{l}^3 -Synuclein in Bladder Carcinoma: A Possible Marker for Prognosis. Anticancer Research, 2016, 36, 951-6.	1.1	3
68	Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Pharmacology, 2022, 13, 840695.	3.5	3
69	Skeletal Muscle Metastasis From Renal Cell Carcinoma: A Case Series and Literature Review. Frontiers in Surgery, 2022, 9, 762540.	1.4	3
70	Analysis of renal lesions in Chinese tuberous sclerosis complex patients with different types of TSC gene mutations. Genetics and Molecular Biology, 2022, 45, .	1.3	3
71	Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years. SpringerPlus, 2014, 3, 357.	1.2	2
72	Primitive neuroectodermal tumour of the kidney: An unusual case mimicking renal angiomyolipoma with minimal fat. Canadian Urological Association Journal, 2015, 9, 337.	0.6	2

#	Article	IF	Citations
73	Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy. Chinese Medical Sciences Journal, 2015, 30, 90-94.	0.4	2
74	Effects of Sunitinib Malate on Growth of Human Bladder Transitional Cell Line T24 In Vitro. Chinese Medical Sciences Journal, 2015, 30, 51-55.	0.4	2
75	Re: Hashim U. Ahmed, Louise Dickinson, Susan Charman, et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. Eur Urol 2015;68:927–36. European Urology, 2016, 70, e131.	1.9	2
76	Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma. Cellular Oncology (Dordrecht), 2016, 39, 15-21.	4.4	2
77	Castleman's Disease. Chinese Medical Journal, 2017, 130, 2126-2127.	2.3	2
78	Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes. Biochemical Genetics, 2021, 59, 902-918.	1.7	2
79	Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy. BMC Urology, 2021, 21, 68.	1.4	2
80	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study Journal of Clinical Oncology, 2012, 30, 4628-4628.	1.6	2
81	PTEN inhibitor VOâ€'OHpic suppresses TSC2â€'/â€' MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Experimental and Therapeutic Medicine, 2020, 19, 3565-3570.	1.8	2
82	Giant multilocular prostatic cystadenoma in a 16-year-old male with difficulty in defecation: case report and literature review. International Journal of Clinical and Experimental Pathology, 2020, 13, 1468-1473.	0.5	2
83	Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms. Chinese Medical Journal, 2014, 127, 261-5.	2.3	2
84	Analysis of serum lipid parameters predicting lipid metabolic disorders in TSCâ€AML patients with treatment of mTOR inhibitors. Journal of Clinical Pharmacy and Therapeutics, 2022, , .	1.5	2
85	Bladder Varices Caused by Portal Hypertension. Cell Biochemistry and Biophysics, 2015, 72, 795-798.	1.8	1
86	Re: Eduard Baco, Erik Rud, Lars Magne Eri, et al. A Randomized Controlled Trial to Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol 2016;69:149–56 European Urology, 2016, 70, e53-e54.	1.9	1
87	Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576–81. European Urology, 2017, 71, e12.	1.9	1
88	Reply. Urology, 2017, 101, 176.	1.0	1
89	Multifocal Paraganglioma and Pheochromocytoma Due to Truncated SDHD Mutation. Urology, 2018, 116, 63-67.	1.0	1
90	<p>Prognostic significance of a novel indicator (PSA_{postd3}/PSA_{pre})Âfor PSA recurrence in patients after radical prostatectomy</p> . Cancer Management and Research, 2019, Volume 11, 5777-5783.	1.9	1

#	Article	IF	CITATIONS
91	Characteristics of Chinese patients with advanced prostate cancer: A muliticentre, non-interventional, observational, prospective, registry study of docetaxel Journal of Clinical Oncology, 2016, 34, 328-328.	1.6	1
92	$1.9\hat{l}\frac{1}{4}$ m Thulium Laser Treats Ureteral Carcinoma via Rigid-ureteroscopy. Chinese Medical Sciences Journal, 2016, 31, 127-128.	0.4	0
93	Re: Kapoor et al.: Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML) (Urology 2016;89:19-26). Urology, 2017, 100, 255.	1.0	0
94	Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs > 4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85–90. European Urology, 2017, 71, e141-e142.	1.9	0
95	Combined thoracoscopic and laparoscopic approach to remove a large retroperitoneal compound paraganglioma: A case report. World Journal of Clinical Cases, 2021, 9, 6935-6942.	0.8	0
96	A multicenter, noncontrolled clinical study of sorafenib adjuvant therapy in advanced renal cell carcinoma Journal of Clinical Oncology, 2014, 32, e15553-e15553.	1.6	0
97	RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis Journal of Clinical Oncology, 2016, 34, 560-560.	1.6	0
98	RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis Journal of Clinical Oncology, 2016, 34, 611-611.	1.6	0
99	Tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma: A phase III trial in progress Journal of Clinical Oncology, 2020, 38, TPS588-TPS588.	1.6	0
100	78â€T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. , 2020, , .		0